Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours (Q35783628)

10 August 2017

title

Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours (English)

1 reference

10 August 2017

Roberta Elisa Rossi

1

1 reference

10 August 2017

Jorge Garcia-Hernandez

2

1 reference

10 August 2017

Tim Meyer

3

1 reference

10 August 2017

Christina Thirlwell

4

1 reference

10 August 2017

Jennifer Watkins

5

1 reference

10 August 2017

Nicholas Guy Martin

6

1 reference

10 August 2017

Martyn Evan Caplin

7

1 reference

10 August 2017

Christos Toumpanakis

8

1 reference

10 August 2017

publication date

1 June 2015

1 reference

Annals of Translational Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

118

1 reference

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Biomarkers in neuroendocrine tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Appropriate requesting of serum tumour markers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Gastroenteropancreatic neuroendocrine tumours

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Enteroendocrine tumors other than carcinoid: a review of clinically significant advances

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Impact of chromogranin A measurement in the work-up of neuroendocrine tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Small intestinal neuroendocrine tumors: prognostic factors and survival.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Endocrine pancreatic tumors: factors correlated with survival

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4481369

Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays

15 November 2018

1 reference

12 December 2020

Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

Chromogranin A levels in chronic liver disease and hepatocellular carcinoma

1 reference

12 December 2020

Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution

1 reference

12 December 2020

Plasma chromogranin a in patients with inflammatory bowel disease

1 reference

12 December 2020

Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study

1 reference

12 December 2020

10.3978/J.ISSN.2305-5839.2015.04.23

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference